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Hemodialysis related induction of interleukin-6 production by periph-
eral blood mononuclear cells. Interleukin-6 (IL-6) has a complex spec-
trum of biological activities, for example, growth and differentiation of
B cells and synthesis of acute-phase proteins by the liver. To evaluate
the role of this cytokine in the inflammatory response induced by blood
interaction with hemodialysis membranes, we have investigated the
IL-6 synthesis and release in supernatant of 24-hour cultured peripheral
blood mononuclear cells (PBMC) isolated from: (a) 10 hemodialyzed
patients, (b) seven patients with advanced chronic renal failure (GFR
slO mI/mm), and (c) eight healthy control subjects. In the same groups
of subjects we evaluated the relationship between IL-6 synthesis and
release and beta-2-microglobulin (f32m) production. Before and after
dialytic treatment hemodialysis patient blood samples were drawn using
the following criteria: (1) after two months of dialysis with cuprophan
membranes, (2) after one and two months of dialysis with polymethyl-
methacrylate (PMMA) membranes, and finally, (3) after one further
month of dialysis with cuprophan membranes. IL-6 was determined
after 72 hours of incubation of PBMC supernatant serial dilutions with
IL-6-dependent hybridoma cell line, 7TD1. Compared to IL-6 synthesis
in control subjects (6.0 5.6 U/3 x 106 PBMC/24 hr), hemodialyzed
patients, when treated with cuprophan membranes, showed signifi-
cantly higher value of IL-6 production both before (23 13 U13 X 106
PBMC/24 hr) and after (26.2 11.3 U/3 x 10 PBMC/24 hr) the dialytic
session. When patients were hemodialyzed with PMMA membranes, at
the start of dialysis IL-6 levels were not significantly different from
values observed in healthy controls (10.6 4 U/3 x 10 PBMC/24 hr,
after 1 month of dialysis and 7.8 U/3 x 106 PBMC/24 hr, after 2 months,
respectively). When the patients were switched back to cuprophan
membranes, IL-6 production was greatly increased after one month of
dialysis (CU2, 44.6 9,4 U/3 x 106 PBMC/24 hr, at the start of dialysis)
reaching values significantly higher than those obtained in the first
period with cuprophan membranes. No difference was observed be-
tween the values of IL-6 production obtained pre- and post-dialysis with
cuprophan or PMMA membranes. IL-6 production values in uremic
non-dialyzed patients were similar to values found in control subjects
(8.6 6.4 U/3 x 106 PBMC/24 hr). f32m release showed a behavior quite
similar to IL-6 throughout the study, In fact, a statistically significant
linear relationship was obtained between j32m and IL-6 values of
production (r = 0.8296, P < 0.001), In conclusion, our results show
higher levels of IL-6 production in hemodialyzed patients treated with
cuprophan membranes, thereby suggesting a chronic stimulation. j3m
production is highly related to IL-6 production; this relationship sug-
gests a possible implication for this cytokine in the pathogenesis of
dialysis amyloidosis.
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Blood interaction with hemodialysis membranes may result
in the activation of circulating leucocytes and production of
inflammatory cytokines [1—10]. These may account for both
acute symptoms, such as fever and hypotension, and chronic
disorders, such as muscle wasting, osteopenia, beta-2-micro-
globulin (f32m) release and amyloidosis, in hemodialyzed pa-
tients [11—18].
Several culprits have been suggested for cytokines induction
during extracorporeal circulation, including complement acti-
vation [19—22], bacterial contamination of dialysate [2, 6, 7, 23,
24], leucocyte adherence [25, 26], and acetate [27]. The type of
dialysis membrane, however, seems to play a critical role
because different membranes activate complement to a different
extent, thus conditioning both cytokine and beta-2-microglob-
ulin release [28—321.
In the past few years, interleukin-6 (IL-6) has emerged as a
monocyte/macrophage product regulating a complex spectrum
of functions, including bone marrow stem cell proliferation, B
lymphocyte differentiation and immunoglobulin secretion, T
lymphocyte activation, acute phase protein induction, and
release of other cytokines such as IL-i and TNF [33—39].
Recently, high plasma levels of IL-6 have been shown in uremic
patients both on RDT and not yet treated with hemodialysis
[40]. The specific effects of hemodialysis per se, and of different
dialysis membranes on IL-6 release by peripheral leucocytes,
however, have not yet been defined and were the object of the
present study. In addition, we investigated the relation between
IL-6 production and beta-2-microglobulin leucocyte synthesis
and release.
Methods
Patients and control subjects
We studied seven patients (4 male, 3 female; age 54.5 years;
age range 38 to 61) with advanced chronic renal failure (GFR,
evaluated with creatinine clearance 9.18 ml/min; range 7 to 10
mi/mm) and 10 hemodialyzed (HD) patients (6 male and 4
female; age 59.4 years; range 40 to 63). For at least one year
prior to the study HD patients were dialyzed with cuprophan
membrane dialyzers three times a week. Five patients used a
bicarbonate bath for more than one year.
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No patient had clinical evidence for infectious or inflamma-
tory diseases or malignancy; none was diabetic nor on steroid
or immunosuppressive therapy.
Eight sex- and age-matched healthy volunteers were included
in the study as controls.
Design of the study
A cross over design was used in the study. In the first phase
of the study all patients were evaluated during dialysis with new
cuprophan membrane (Bellco Italy; membrane surface 1.0 m2;
membrane thickness 11 t; sterilization, ethylene oxide) for two
months. The patients were then switched to dialysis with
polymethylmethacrylate (PMMA, Toray, Tokyo, Japan; mem-
brane surface 1.0 m2; membrane thickness 30 sterilization,
gamma ray) for two months; finally, they were then switched to
a second period of dialysis with new cuprophan membrane
(same filter of the first period) for one additional month. There
were no changes throughout all phases of the study in the
following dialysis parameters: axial blood flow, ultrafiltration
flow rate, dialysis time and dialysate flow rate and composition
(5 patients used bicarbonate bath and 5 patients used acetate
bath thorough all the study). In all dialysis sessions (during the
3 phases of the study) we used the same type of blood lines
(PiVipOIR, BelIco Italy).
During the different phases of the study patients were mea-
sured two times a month, at midweek, for predialysis BUN and
serum creatinine concentrations.
Blood samples
Blood samples (15 ml) were collected in heparinized tubes in
controls and uremic (dialyzed and non-dialyzed) patients. In
dialyzed patients blood samples were obtained before and after
dialytic session: at the end of the first cuprophan period (CU 1),
at the end of each month of treatment with PMMA (PMMA1
and PMMA2, respectively) and at the end of the second
cuprophan period (CU2).
IL-6 and 2m production was measured in supernatant of
peripheral blood mononuclear cells (PBMC) isolated and cul-
tured for 24 hours.
Preparation of PBMC
Fifteen milliliters of whole blood were carefully layered over
lymphocytes-separation medium (Flow Laboratories, Irvine,
Scotland, UK) allowing gradient density centrifugation. Cell
pellets were washed twice with RPMI 1640 (Flow Laborato-
ries), counted using a coulter counter and then resuspended at
3 x 106/ml, in Iscove's (Flow Laboratories) containing 1%
de-complemented fetal calf serum (Gibco), 100 lU/mi penicillin
(Gibco) and 100 Wml streptomycin (Gibco). On average,
PBMC contained 80% of lymphocytes and 20% of monocytes.
The average percents of monocytes were not different (range 18
to 21%) in the various groups (controls, uremics, CU1, PMMA
and CU2).
PBMC were placed in 15 ml polypropylene round-bottom
tubes (Falcon), at 37°C in a 5% CO2 saturated humidity incu-
bator. After 24 hours of incubation the supernatant was re-
moved.
7TDI bioassay of IL-6
In agreement with other authors [401, it is well established
that average sensitivity of IL-6 bioassay is about 50 to 100 times
greater than that of IL-6 immunoassay (ELISA). Therefore, we
decided to measure IL-6 supernatant levels by IL-6 activity
assay. In particular, IL-6 levels were determined by the capac-
ity to induce the proliferation of IL-6-dependent murine hybrid-
oma cell line, (provided by Dr. J. Van Snick, Ludwig Institute
for Cancer Research, Brussels, Belgium) [41, 42]. 7TD1 cells
are cultured in Iscove's medium (Flow Laboratories) supple-
mented with 10% heat-inactivated fetal calf serum (Flow Lab-
oratories), 1.5 mrvi L-glutamine, 0.24 mrvi L-asparagine, 0.55
mM L-arginine, 50 /LM 2-mercaptoethanol, 0.1 mt hypoxan-
thine, 16 LM thymidine, 50 pg/mi gentamicin, and at least 20
U/mi (0.02 to 0.2 ng/ml) of human recombinant IL-6 (rIL-6, 1 x
i07 U/ml, provided by Dr. T. Kishimoto, Division of Immunol-
ogy, Institute for Molecular and Cellular Biology, Osaka Uni-
versity, Osaka, Japan).
Before the assay, spent medium is removed and cells are
washed twice with fresh medium (without IL-6) to eliminate
traces of remaining IL-6. Cells are then resuspended in culture
medium (without cold thymidine and IL-6) at 20,000 cells/mi
and 100 d of this suspension is added to duplicate serial
dilutions of samples in the same volume. Incubation is carried
out in 96-well, flat-bottom, gamma irradiated plates (Microtest
III, Becton Dickinson, New Jersey, USA) for 72 hours. Differ-
ent dilutions of recombinant human IL-6 are also included in the
same volume of the samples (100 d) to verify the validity of the
bio-assay.
7TD1 growth factor activity was determined by measuring
tritiated timidine incorporation in the cells. To measure timidine
incorporation, 7TD1 cultures were pulsed with 0.5 nCi of
[3H]-thimidine (Amersham International, London UK, specific
activity 48 Ci/mmol) for the last four hours and collected by an
automated cell harvester (Packard Micromate 196, Packard
Instruments Company, Meriden, Connecticut, USA). Thimi-
dine incorporation in cells was determined in the samples, as
cpm, by a scintillation counter (Packard 1500 Tri-Carb).
IL-6 activity in experimental samples was measured in U/mi.
One IL-6 unit was defined as the dilution that produces the
half-maximal growth of the cells [41].
Under these conditions, the lowest detectable concentration
of IL-6 in supernatant from the zero level was 4 U/mI. Super-
natant samples below this detection limit were assumed to have
a value of 2 U/ml. This detection limit corresponds on average
to 8 pg/mI, and is lower than the limits reported by others for
commercially available immunoassays [401.
In our laboratory, we tested and recently reported [43] the
specificity of the 7TD1 response to IL-6 with an anti-IL-6 goat
polyclonal neutralizing antibody.
Beta-2-microglobulin assay
The quantity of /32m released by PBMC after 24 hours of
incubation was determined in the supernatant by using solid-
phase radioimmunoassay (Abbott, Germany). The titration
curve was linear from 50 to 4000 nglml, with an interassay
variation of less than 3%.
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Fig. 2. IL-6 production after incubating PBMC for 24 hours. Results
from 10 dialyzed patients before (0) andafter () dialysis session. The
IL-6 values were obtained at the end of the first period of dialysis with
cuprophan membranes (CU!), after one (PMMA1) and two (PMMA2)
months of dialysis with polymethylmethacrylate membranes and after
one further month of dialysis with cuprophan membranes (CU2). IL-6
production in CU! (both pre and post dialysis) were significantly greater
than in PMMAI and PMMA2 (P < 0.01). IL-6 production in CU2 were
significantly greater than in CU! (P < 0.05), PMMA1 and PMMA2 (P <
0.01).
Effects of different membranes. IL-6 production was different
with different membranes. Thus, the values obtained with
_____________________________ PMMA membranes after one month (PMMAI = 10.6 4.0 U/3
x 106 PBMC/24 hr, at the start of dialysis) and after two months
(PMMA2 = 7.8 4.4 U/3 x 106 PBMC/24 hr, at the start of
dialysis) of dialysis were not different from controls and much
lower than those obtained after cuprophan (Fig. 2).
When the patients were switched back to the new cuprophan
membrane, the IL-6 production by their PBMC in culture was
greatly increased after one month of dialysis (CU2, 44.6 9.4
U/3 x 106 PBMC/24 hr, at the start of dialysis) reaching values
significantly higher than those obtained with the first period
with cuprophan membrane (Fig. 2).
Effect of dialytic treatment. No difference was observed
between the values of IL-6 production obtained pre- and
post-dialysis with cuprophan or PMMA membranes (Fig. 2). No
difference was obtained between the patients using acetate and
those using bicarbonate bath.
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Fig. 1. IL-6 production after incubating PBMC for 24 hours. Results
from 8 healthy subjects (C), 7 uremic non-dialyzed patients (UR) and 10
dialyzed patients (at the start of dialysis session, at the end of first
period of dialysis with cuprophan membranes, CU 1). IL-6 production in
CUI is significantly greater than in C (P < 0.005) and UR (P < 0.05).
Statistical analysis
Stttistical analysis was carried out using the analysis of
variance for repeated measures (Newman-Keuls), paired t-test
and regression analysis (BMDP software). The differences were
considered to be significant for P < 0.05.
Results
Comparison among controls, uremic non-dialyzed and hemo-
dialyzed patients. Figure 1 shows IL-6 production obtained in
eight control subjects (C), in seven uremic non-dialyzed pa-
tients (UR) and in ten patients on RDT (at the start of dialysis
session) with cuprophan membranes (CU1).
Compared to IL-6 synthesis in control healthy subjects (6.0
5.6 U13 x 106 PBMC/24 hr) and UR patients (8.6 6.4 U/3 )<
106 PBMC/24 hr), the patients usually dialyzed with new
cuprophan membranes (CU 1) showed a statistically-significant
higher value of IL-6 production (23 13 U/3 x 106 PBMCI24
hr, at the start of dialysis). No difference was observed between
UR patients and control subjects.
In Figure 3 the values of f32m production by PBMC are shown
for controls, non-dialyzed uremic patients and dialyzed pa-
tients.
The values of f32m release were significantly greater in
patients dialyzed with cuprophan membrane (CU1 and CU2)
than in controls (C), uremic non-dialyzed patients (UR) and
patients dialyzed with PMMA membranes (PMMA1 and
PMMA2), with no difference between the values obtained
before and after dialytic treatment.
/32m release obtained at the end of the second cuprophan
period was significantly higher than the value obtained at the
end of the first cuprophan period (Fig. 3).
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Fig. 3. Beta-2-microglobulin production after
incubating PBMC for 24 hours. Results in 8
control subjects (C), 7 uremic non-dialyzed
patients (UR) and 10 dialyzed patients before(3) and after () dialysis session at the end
of the first period of dialysis with cuprophan
membranes (CU1), after one (PMMAI) and
two (PMMA2) months of dialysis with
polymethylmethacrylate membranes and after
one further month of dialysis with cuprophan
membranes (CU2). Beta-2-microglobulin
values in CU! (both pre- and post-dialysis)
were significantly greater than in C, UR,
PMMA1 and PMMA2 (P < 0.01). Beta-2-
microglobulin values in CU2 (both pre- and
_______ __________ post-dialysis) were significantly greater than in
CUI (P < 0.05) and C, UR, PMMAI and
PMMA2 (P < 0.01).
Fig. 4. Comparison between IL-6 (--0--) and
beta-2-microglobulin (t) productions in
uremic non-dialyzed patients (UR) and
dialyzed patients (before dialysis session) at
the end of first period of dialysis with
cuprophan membranes (CUJ), after one
(PMMAJ) and two (PMMA2) months of
dialysis with polymethylmethacrylate
membranes, and after one further month of
dialysis with cuprophan membranes (CU2).
Relationship between IL-6 and f32m production
The behavior of IL-6 and that of /32m were quite similar
throughout the study, as shown in Figure 4.
A linear relation was obtained when values of /32m production
were plotted against values of IL-6 production (r =0.8296, P <
0.001; Fig. 5).
Since the inclusion of several samples from the same sub-
jects, that is, hemodialyzed patients, might influence the regres-
sion analysis, intercorrelations of IL-6 or /32m production
values for different dialysis membranes were also calculated.
No significant correlation among these values was found,
confirming the independence of the observations from the same
subjects.
Finally, no differences were observed in BUN (respectively
70.05 12.13, 72.17 14.38 and 69.20 9.17 mg/dl) and serum
creatinine (respectively 9.28 2.57, 9.76 2.93 and 9.04 2.40
mgfdl) concentrations registered two times a month in hemodi-
alyzed patients during the three different periods of the study
(CU1, PMMA and CU2).
Discussion
In this study, we have shown that PBMC of uremic patients
regularly hemodialyzed with a cuprophan dialyzer produce
higher amounts of IL-6 in culture than PBMC from normal
subjects or non-dialyzed uremic patients. These findings clearly
indicate that the interaction of PBMC with cuprophan activates
PBMC and suggest that the high levels of plasma IL-6 found by
others in dialyzed patients [40] is secondary to increased in vivo
production by circulating cells.
IL-6 production was high in PBMC sampled from hemodia-
lyzed patients both before and after a single dialytic session,
indicating that regular dialysis treatment with a cuprophan
membrane causes prolonged activation of monocytes.
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After dialyzing the same patients for one month with PMMA,
a reduction of IL-6 production by PBMC was observed, which
was similar to those of uremic non-dialyzed patients and
healthy control subjects. This reduction was confirmed after
two months. This effect of PMMA proves further that PMMA is
more biocompatible than cuprophan, and may be accounted for
by the low capacity of PMMA membranes to activate comple-
ment [29].
Recently, Vanholder et al [44] suggested that accumulation of
uremic solutes could play a role in chronic stimulation of
monocytes. In our study, no differences were observed in small
molecules (BUN and creatinine) concentrations during the
different phases of the study (when either cuprophan or PMMA
were used); these results seem to exclude any role of a different
accumulation of these solutes on monocytes chronic activation.
When the patients were switched back to dialysis with
cuprophan membranes a great increase of IL-6 production was
observed, with values significantly greater than those obtained
with cuprophan before PMMA (Fig. 2). This behavior suggests
a more intense responsiveness of PBMC after a period of
PMMA dialysis; such observation is consistent with that of
Zaoui, Stone and Hakim [32], who have recently demonstrated
that dialysis with PMMA membranes increases HLA and f3,m
expression on circulating cells. It is likely that synthesis of IL-6
during the first period of dialysis with cuprophan was reduced
because of the repetitive stimulation of monocytes prior to
testing, whereas during the second exposure to cuprophan, the
monocytes had not been activated for a prolonged period of
time and were therefore able to up-regulate their synthesis
quickly.
The high production of IL-6 by PBMC may have important
clinical implications since it is well known that elevated IL-6
plasma levels can play a role in the systemic inflammatory
reaction to an infection or injury. Studies using highly sensitive
IL-6-dependent hybridoma growth assays show that IL-6 levels
are elevated in patients who develop an acute phase response
with changes in circulating protein levels [45, 46].
Interleukin-6 is the major regulator of the hepatic acute phase
protein response during inflammation [47—52]. In humans,
changes referred to acute phase proteins are characterized by
decreased synthesis of albumin, modest increase in synthesis of
a number of positive acute phase proteins and, most strikingly,
by dramatic increase in synthesis (up to 1000-fold or more) of
the two major acute phase proteins, C-reactive protein and
serum amyloid A [49). These effects are observed also in vitro
upon stimulation of hepatocytes with human rIL-6 [48, 49].
There are no studies in the literature on the effect of IL-6
plasma levels in uremic patients on the release of acute phase
proteins. We can only hypothesize that repeated inductions of
acute phase proteins may cause complications mainly related to
amyloidosis disease, including carpal tunnel syndrome, Os-
teopenia, joint fibrosis and muscle wasting [53]. Further inves-
tigations with measurement of acute phase protein release in
uremic patients are, however, needed to clarify this important
issue.
Our results demonstrate that the production of /32m by PBMC
is different with different types of membranes used for dialysis
treatment (Fig. 3) and that the 132m production is related to IL-6
production (Figs. 4 and 5). This relationship further suggests a
possible implication of this cytokine in the pathogenesis of
dialysis amyloidosis.
Interestingly, uremic non-dialyzed patients show a low 132m
release, as well as a low IL-6 production (Figs. 2, 3 and 4).
In conclusion, the production of IL-6 by PBMC of uremic
patients treated with cuprophan dialyzers is increased. In
PBMC, the increased production of IL-6 is associated with
increased 2m release. Both the abnormal IL-6 production and
the increased release of J3,m are normalized after an one-month
treatment with a more biocompatible membrane.
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ure,nic non-dialyzed patients and dialyzed
patients, at the start of dialysis, in all phases
of the study. P < 0.001; r = 0.8270; y =
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